Ulrike Leiter

11.7k total citations · 4 hit papers
185 papers, 6.4k citations indexed

About

Ulrike Leiter is a scholar working on Oncology, Epidemiology and Molecular Biology. According to data from OpenAlex, Ulrike Leiter has authored 185 papers receiving a total of 6.4k indexed citations (citations by other indexed papers that have themselves been cited), including 140 papers in Oncology, 77 papers in Epidemiology and 64 papers in Molecular Biology. Recurrent topics in Ulrike Leiter's work include Cutaneous Melanoma Detection and Management (107 papers), Nonmelanoma Skin Cancer Studies (76 papers) and Melanoma and MAPK Pathways (44 papers). Ulrike Leiter is often cited by papers focused on Cutaneous Melanoma Detection and Management (107 papers), Nonmelanoma Skin Cancer Studies (76 papers) and Melanoma and MAPK Pathways (44 papers). Ulrike Leiter collaborates with scholars based in Germany, Australia and United States. Ulrike Leiter's co-authors include Claus Garbe, Thomas Eigentler, Ulrike Keim, Friedegund Meier, Helmut Breuninger, Peter Kaskel, Gertraud Krähn, Andrea Forschner, Peter Martus and Konstantinos Lasithiotakis and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Ulrike Leiter

171 papers receiving 6.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Epidemiology of Melanoma and Nonmelanoma Skin Cancer—The Role of Sunlight

2009 524 citations Ulrike Leiter, Claus Garbe profile →
Epidemiology of Skin Cancer

2014 446 citations Ulrike Leiter, Thomas Eigentler et al. profile →
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial

2016 405 citations Ulrike Leiter, Carola Berking et al. profile →
Epidemiology of Skin Cancer: Update 2019

2020 276 citations Ulrike Leiter, Ulrike Keim et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ulrike Leiter Germany	38	4.3k	2.1k	2.1k	1.9k	982	185	6.4k
Philippe Saïag France	38	3.2k 0.8×	1.6k 0.8×	1.8k 0.9×	1.6k 0.9×	729 0.7×	212	6.3k
Pietro Quaglino Italy	45	3.1k 0.7×	2.2k 1.0×	1.5k 0.7×	3.5k 1.9×	2.6k 2.6×	449	8.2k
Martin Cook United Kingdom	41	3.3k 0.8×	1.5k 0.7×	1.7k 0.8×	938 0.5×	577 0.6×	148	5.7k
Thomas Eigentler Germany	48	6.3k 1.5×	1.5k 0.7×	3.4k 1.7×	1.2k 0.6×	2.5k 2.5×	264	9.2k
Mark B. Faries United States	42	5.9k 1.4×	1.5k 0.7×	2.6k 1.3×	570 0.3×	2.2k 2.2×	173	7.5k
Alan Spatz France	45	4.7k 1.1×	863 0.4×	3.4k 1.6×	851 0.5×	1.8k 1.8×	200	7.7k
Karl D. Lewis United States	41	4.9k 1.1×	1.5k 0.7×	4.0k 1.9×	1.0k 0.6×	1.5k 1.5×	177	7.8k
David Polsky United States	43	3.7k 0.9×	727 0.3×	3.9k 1.9×	943 0.5×	833 0.8×	124	6.8k
Laurent Mortier France	43	4.7k 1.1×	1.5k 0.7×	3.4k 1.7×	1.1k 0.6×	1.7k 1.7×	307	8.1k
Stefania Staibano Italy	43	2.4k 0.6×	725 0.3×	2.8k 1.3×	646 0.3×	730 0.7×	229	6.5k

Countries citing papers authored by Ulrike Leiter

Since Specialization

Citations

This map shows the geographic impact of Ulrike Leiter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrike Leiter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrike Leiter more than expected).

Fields of papers citing papers by Ulrike Leiter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulrike Leiter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrike Leiter. The network helps show where Ulrike Leiter may publish in the future.

Co-authorship network of co-authors of Ulrike Leiter

This figure shows the co-authorship network connecting the top 25 collaborators of Ulrike Leiter. A scholar is included among the top collaborators of Ulrike Leiter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrike Leiter. Ulrike Leiter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lodde, Georg, Ulrike Leiter, Anja Gesierich, et al.. (2025). Clinical course of Merkel cell carcinoma: A DeCOG multicenter study of 1049 patients. European Journal of Cancer. 221. 115406–115406. 1 indexed citations

Lallas, Konstantinos, Philipp Tschandl, Harald Kittler, et al.. (2025). Machine learning algorithms using dermatoscopy for the prediction of melanoma prognosis: A narrative review of the literature. SHILAP Revista de lepidopterología. 3. 100766–100766.

Schäffeler, Norbert, et al.. (2025). Psychosocial distress and persistent adverse events in long‐term survivors of stage IV melanoma – a cross‐sectional questionnaire study. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 23(7). 832–842. 1 indexed citations

Becker, Jürgen C., Anja Gesierich, Ulrike Leiter, et al.. (2025). Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial. British Journal of Dermatology. 193(5). 865–875.

Utikal, Jochen, Verena Müller, Jürgen C. Becker, et al.. (2024). S1‐Guideline Sebaceous Carcinoma. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 22(5). 730–747. 3 indexed citations

Forschner, Andrea, et al.. (2024). Response and outcome of patients with melanoma skin metastases and immune checkpoint inhibition. International Journal of Cancer. 156(1). 145–153. 4 indexed citations

Weichenthal, Michael, Inge Marie Svane, Johanna Mangana, et al.. (2024). Real-World efficiency of pembrolizumab in metastatic melanoma patients following adjuvant anti-PD1 treatment. SHILAP Revista de lepidopterología. 2. 100271–100271. 1 indexed citations

Keim, Ulrike, et al.. (2024). Epidemiology of Keratinocyte Skin Cancer with a Focus on Cutaneous Squamous Cell Carcinoma. Cancers. 16(3). 606–606. 22 indexed citations

Keim, Ulrike, Alexander Katalinic, Bernd Holleczek, et al.. (2023). Incidence, mortality and trends of cutaneous squamous cell carcinoma in Germany, the Netherlands, and Scotland. European Journal of Cancer. 183. 60–68. 25 indexed citations

10.

Leiter, Ulrike, et al.. (2023). Sentinel lymph node biopsy for lentigo maligna melanoma under local anaesthesia. Journal of the European Academy of Dermatology and Venereology. 38(1). 84–92. 2 indexed citations

11.

Zimmer, Lisa, Selma Ugurel, Friedegund Meier, et al.. (2023). Effects of an immunosuppressive therapy on the efficacy of immune checkpoint inhibition in metastatic melanoma – An analysis of the prospective skin cancer registry ADOREG. European Journal of Cancer. 198. 113508–113508. 2 indexed citations

12.

Forchhammer, Stephan, et al.. (2022). Transcription Properties of Beta-HPV8 and HPV38 Genomes in Human Keratinocytes. Journal of Virology. 96(23). e0149822–e0149822. 3 indexed citations

13.

Hassel, Jessica C., Michael Sachse, Ulrike Leiter, et al.. (2022). Reinduction of Hedgehog Inhibitors after Checkpoint Inhibition in Advanced Basal Cell Carcinoma: A Series of 12 Patients. Cancers. 14(21). 5469–5469. 3 indexed citations

14.

Serna-Higuita, Lina María, Teresa Amaral, Andrea Forschner, et al.. (2021). Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry. Cancers. 13(23). 6141–6141. 16 indexed citations

15.

Amaral, Teresa, Ulrike Keim, Ulrike Leiter, et al.. (2020). Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry. Journal of the European Academy of Dermatology and Venereology. 34(9). 2021–2025. 16 indexed citations

16.

Amaral, Teresa, et al.. (2019). Advanced cutaneous squamous cell carcinoma: real world data of patient profiles and treatment patterns. Journal of the European Academy of Dermatology and Venereology. 33(S8). 44–51. 30 indexed citations

17.

Heppt, Markus V., Theresa Steeb, Lutz Schmitz, et al.. (2019). Harmonisation of Outcome Parameters and Evaluation (HOPE) for actinic keratosis: protocol for the development of a core outcome set. Trials. 20(1). 589–589. 5 indexed citations

18.

Alter, Mareike, Uwe Hillen, Ulrike Leiter, Michael Sachse, & Ralf Gutzmer. (2015). Current diagnosis and treatment of basal cell carcinoma. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 13(9). 863–875. 36 indexed citations

19.

Leiter, Ulrike, Michael Weichenthal, Annette Pflugfelder, et al.. (2013). Diagnosis and Follow-up of Melanoma - what will change with the new S3 Guideline?. Queensland's institutional digital repository (The University of Queensland). 11. 56–56. 1 indexed citations

20.

Held, Laura, Thomas Eigentler, Gisela Metzler, et al.. (2012). Proliferative Activity, Chromosomal Aberrations, and Tumor-Specific Mutations in the Differential Diagnosis between Blue Nevi and Melanoma. American Journal Of Pathology. 182(3). 640–645. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact